NCT03804554已完成不适用
Nivolumab in the Treatment of Patients With Non-small Cell Lung Cancer: The Australian Experience
Bristol-Myers Squibb1 个研究点 分布在 1 个国家目标入组 503 人开始时间: 2018年10月3日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 503
- 试验地点
- 1
- 主要终点
- Time to treatment failure (TTF)
研究概览
简要总结
This study is to capture and describe the patient and disease characteristics and the outcomes of adult patients with previously-treated advanced NSCLC who have been treated with Nivolumab
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- •Insufficient data available
- •Other protocol defined inclusion/exclusion criteria could apply
结局指标
主要结局
Time to treatment failure (TTF)
时间窗: Approximately 27 months
次要结局
- Incidence of SAE's(Approximately 27 months)
- Incidence of re-treatment(Approximately 27 months)
- Progression free survival rate (PFSR)(Approximately 27 months)
- Incidence of AE's(Approximately 27 months)
- Best overall response (BOR)(Approximately 27 months)
- Overall survival rate (OSR)(Approximately 27 months)
- Reasons for ceasing treatment(Approximately 27 months)
- Incidence of patients with brain metastases(Approximately 27 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Study of Nivolumab in Patients With Classical Hodgkin's Lymphoma (Registrational)Hodgkin DiseaseNCT02181738Bristol-Myers Squibb294
进行中（未招募）
2 期
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkerJPRN-jRCTs031180013Kagamu Hiroshi60
已完成
不适用
Phase II study Nivolumab in previously treated non-small-cell lung cancer subjects to evaluate the peripheral blood mononuclear cell immunological biomarkernon-small-cell lung cancerJPRN-UMIN000028468orst East Japan Study Group(NEJSG)60
已完成
不适用
Cohort of Patients With NSCLC Treated With Nivolumab Under the ATU ProgramNivolumabLong-term Adverse EffectsNon-small Cell Lung CancerNCT02933346Intergroupe Francophone de Cancerologie Thoracique907
终止
1 期
Nivolumab Role in the Treatment of Patients With Refractory or Relapse Multiple MyelomaMultiple MyelomaNCT03023527PETHEMA Foundation6